1. Peter Arlett, Corinne de Vries, Henry Fitt (2014) Demonstrating impact for public health and stakeholders: focus on pharmacovigilance. Joint meeting: Patients and Consumers and Healthcare Professionals working parties. 16 Sept 2014. http://www.ema.europa.eu/docs/en_GB/document_library/Presentation/2014/11/WC500177755.pdf
2. Gurwitz JH, Field TS, Radford MJ (2007) The safety of warfarin therapy in the nursing home setting. Am J Med 120:539–544
3. (a) Opioid addiction 2015 Facts & Figures American Society of Addiction Medicine. http://www.asam.org/docs/default-source/advocacy/opioid-addiction-disease-facts-figures.pdf . (b) Rudd RA, Aleshire N, Zibbell JE, Matthew Gladden R (2015) Morbidity and Mortality Weekly Report (MMWR) increases in drug and opioid overdose deaths—United States, 2000–2014 Dec 18, 64;1–5. http://www.cdc.gov/mmwr/preview/mmwrhtml/mm64e1218a1.htm?s_cid=mm64e1218a1_e
4. Hayes MJ, Brown MS (2012) Epidemic of prescription opiate abuse and neonatal abstinence. JAMA 307(18):1974–1975
5. National Action Plan for Adverse Drug Event Prevention U.S. Department of Health and Human Services, Office of Disease Prevention and Health Promotion (2014). http://health.gov/hcq/pdfs/ade-action-plan-508c.pdf